摘要
老年(>60岁)弥漫大B细胞淋巴瘤(DLBCL)患者的预后明显差于年轻患者,目前尚无标准治疗方案。老年DLBCL患者异质性较大,在治疗前对老年DLBCL患者进行分层,有助于实现精准化治疗,从而改善预后。R-CHOP方案(利妥昔单抗联合环磷酰胺、长春新碱、多柔比星、强的松)仍是一般状况较好的老年DLBCL患者的推荐治疗方案,一般状况较差或超高龄的患者则应考虑低剂量的化疗或其他姑息性治疗方案。复发/难治的老年DLBCL患者可选择的治疗方案有限,耐受性好的新药或新的治疗方案具有良好的应用前景。
The prognosis of elderly(>60 years)patients with diffuse large B-cell lymphoma(DLBCL)is significantly worse compared with young patients,and there is currently no standard treatment.Elderly patients with DLBCL are highly heterogeneous,a stratification before treatment can help achieve precise medicine and improve outcome of them.R-CHOP(rituximab,cyclophosphamide,vincristine,doxorubicin and prednisolone)is still the recommended treatment for fit elderly DLBCL patients;and for unfit or very old patients,chemotherapy of reduced dose or palliative treatments should be considered.Choices for relapsed or refractory patients are limited,and novel compounds or therapies that are well tolerated may have a good application prospect.
作者
李巧佴
邹立群
Li Qiao'er;Zou Liqun(West China School of Medicine,Sichuan University,Chengdu 610041,China;First Department of Oncology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《国际肿瘤学杂志》
CAS
2021年第5期317-320,共4页
Journal of International Oncology
关键词
弥漫大B细胞淋巴瘤
老年患者
治疗
Diffuse large B-cell lymphoma
Elderly patients
Treatment
